公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women | Wang Z.; Seow W.-J.; Shiraishi K.; Hsiung C.A.; Matsuo K.; Liu J.; Chen K.; Yamji T.; Yang Y.; Chang I.-S.; Wu C.; Ho J.C.M.; Chan J.K.C.; Wang J.-C.; Lu D.; Zhao X.; Zhao Z.; Wu J.; Chen H.; Jin L.; Wei F.; Hong Y.-C.; Wu G.; An S.-J.; Zhang X.-C.; Su J.; Wu Y.-L.; Gao Y.-T.; Xiang Y.-B.; He X.; Li J.; Zheng W.; Burdett L.; Shu X.-O.; Cai Q.; Klein R.; Pao W.; Lawrence C.; Hosgood H.D.; III, Hsiao C.-F.; Chien L.-H.; Chen Y.-H.; Chen C.-H.; Wyatt K.; Wang W.-C.; Chen C.-Y.; Wang C.-L.; CHONG-JEN YU ; Chen H.-L.; Su Y.-C.; Tsai F.-Y.; Chen Y.-S.; Li Y.-J.; Yang T.-Y.; Chung C.C.; Lin C.-C.; PAN-CHYR YANG ; Wu T.; Lin D.; Zhou B.; Yu J.; Shen H.; Kubo M.; Chanock S.J.; Rothman N.; Li S.A.; Lan Q.; Yeager M.; Hutchinson A.; Hu W.; Caporaso N.; Landi M.T.; Chatterjee N.; Song M.; Fraumeni J.F.; Jr.; Kohno T.; Yokota J.; Kunitoh H.; Ashikawa K.; Momozawa Y.; Daigo Y.; Mitsudomi T.; Yatabe Y.; Hida T.; Hu Z.; Dai J.; Ma H.; Jin G.; Song B.; Wang Z.; Cheng S.; Yin Z.; Li X.; Ren Y.; Guan P.; Chang J.; Tan W.; Chen C.-J.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Huang M.-S.; Chen Y.-M.; Zheng H.; Li H.; Cui P.; Guo H.; Xu P.; Liu L.; Iwasaki M.; Shimazu T.; Tsugane S.; Zhu J.; Jiang G.; Fei K.; Park J.Y.; Kim Y.H.; Sung J.S.; Park K.H.; Kim Y.T.; Jung Y.J.; Kang C.H.; Park I.K.; Kim H.N.; Jeon H.-S.; Choi J.E.; Choi Y.Y.; Kim J.H.; Oh I.-J.; Kim Y.-C.; Sung S.W.; Kim J.S.; Yoon H.-I.; Kweon S.-S.; Shin M.-H.; Seow A.; Chen Y.; Lim W.-Y.; Liu J.; Wong M.P.; Lee V.H.F.; Bassig B.A.; Tucker M.; Berndt S.I.; Chow W.-H.; Ji B.-T.; Wang J.; Xu J.; Sihoe A.D.L. | Human Molecular Genetics | 40 | 34 | |
2014 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer | Chao Y.; Hsieh J.-S.; Yeh H.-T.; Su Y.-C.; Wu C.-C.; Chen J.-S.; Tai C.-J.; Bai L.-Y.; KUN-HUEI YEH ; Su W.-C.; Li C.-P. | Cancer Chemotherapy and Pharmacology | 12 | 9 | |
2020 | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | Chen Y.-M.; CHIH-HSIN YANG ; Su W.-C.; Chong I.-W.; Hsia T.-C.; Lin M.-C.; Chang G.-C.; Chiu C.-H.; CHAO-CHI HO ; Wu S.-Y.; Hung J.-Y.; Wang C.-C.; Yang T.-Y.; CHONG-JEN YU | Journal of the Formosan Medical Association | 7 | 5 | |
2016 | Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancer | Jen J.; Lin L.-L.; Chen H.-T.; Liao S.-Y.; Lo F.-Y.; Tang Y.-A.; Su W.-C.; Salgia R.; CHIA-LANG HSU ; Huang H.-C.; Juan H.-F.; Wang Y.-C. | Oncogene | 35 | 35 | |
2014 | An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer | Stadler W.M.; Vaughn D.J.; Sonpavde G.; Vogelzang N.J.; Tagawa S.T.; Petrylak D.P.; Rosen P.; CHIA-CHI LIN ; Mahoney J.; Modi S.; Lee P.; Ernstoff M.S.; Su W.-C.; Spira A.; Pilz K.; Vinisko R.; Schloss C.; Fritsch H.; Zhao C.; Carducci M.A. | Cancer | 76 | 73 | |
2004 | Oral administration of a mite allergen expressed by zucchini yellow mosaic virus in cucurbit species downregulates allergen-induced airway inflammation and IgE synthesis | Hsu C.-H.; Lin S.-S.; Liu F.-L.; Su W.-C.; SHIH-SHUN LIN | Journal of Allergy and Clinical Immunology | 51 | 50 | |
2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 452 | 443 | |
2020 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study | Sequist L.V.; Han J.-Y.; Ahn M.-J.; Cho B.C.; Yu H.; Kim S.-W.; CHIH-HSIN YANG ; Lee J.S.; Su W.-C.; Kowalski D.; Orlov S.; Cantarini M.; Verheijen R.B.; Mellemgaard A.; Ottesen L.; Frewer P.; Ou X.; Oxnard G. | The Lancet Oncology | 278 | 252 | |
2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
2019 | A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | CHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J. | British Journal of Cancer | 15 | 12 | |
2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN | JTO Clinical and Research Reports | 4 | 0 | |
2013 | Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation | Kwak E.L.; Shapiro G.I.; Cohen S.M.; Becerra C.R.; Lenz H.-J.; WEN-FANG CHENG ; Su W.-C.; Robohn M.; Le Maulf F.; Lobmeyer M.T.; Chand V.K.; Iafrate A.J. | Cancer | 21 | 19 | |
2021 | Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors | Shiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. | Oncologist | 2 | 0 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
2009 | A polymorphism in the APE1 gene promoter is associated with lung cancer risk | Lo Y.-L.; Jou Y.-S.; Hsiao C.-F.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Chi Y.H.; Chen C.-J.; Hsiung C.A. | Cancer Epidemiology Biomarkers and Prevention | 74 | 71 | |
2011 | Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers | Lo Y.-L.; Hsiao C.-F.; Jou Y.-S.; Chang G.-C.; Tsai Y.-H.; Su W.-C.; KUAN-YU CHEN ; Chen Y.-M.; Huang M.-S.; Hsieh W.-S.; Chen C.-J.; Hsiung C.A. | Lung Cancer | 52 | 50 | |
2019 | Postural Control and Interceptive Skills in Children with Autism Spectrum Disorder | LI-CHIOU CHEN ; Su W.-C.; Ho T.-L.; LU LU ; WEN-CHE TSAI ; YEN-NAN CHIU ; SUH-FANG JENG | Physical Therapy | 16 | 14 | |
2019 | Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice | Chen Y.-C.; Su Y.-C.; Shieh G.-S.; Su B.-H.; Su W.-C.; PEI-HSIN HUANG ; Jiang S.-T.; Shiau A.-L.; Wu C.-L. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 3 | 5 | |
2015 | R331W missense mutation of oncogene YAP1 is a germline risk allele for lung adenocarcinoma with medical actionability | Chen H.-Y.; SUNG-LIANG YU ; Ho B.-C.; KANG-YI SU ; Hsu Y.-C.; Chang C.-S.; Li Y.-C.; Yang S.-Y.; Hsu P.-Y.; Ho H.; Chang Y.-H.; Chen C.-Y.; Yang H.-I.; Hsu C.-P.; Yang T.-Y.; Chen K.-C.; Hsu K.-H.; Tseng J.-S.; Hsia J.-Y.; Chuang C.-Y.; Yuan S.; Lee M.-H.; Liu C.-H.; Wu G.-I.; Hsiung C.A.; Chen Y.-M.; Wang C.-L.; Huang M.-S.; CHONG-JEN YU ; KUAN-YU CHEN ; Tsai Y.-H.; Su W.-C.; HUEI-WEN CHEN ; Chen J.J.W.; Chen C.-J.; Chang G.-C.; PAN-CHYR YANG ; Li K.-C. | Journal of Clinical Oncology | 76 | 71 | |